Matthew J Kempton
Overview
Explore the profile of Matthew J Kempton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
3723
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Cox J, De Groot M, Cole J, Williams S, Kempton M
Clin Rheumatol
. 2022 Dec;
42(2):319-326.
PMID: 36534349
A comprehensive search of published literature in brain volumetry was conducted in three autoimmune diseases - systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and ulcerative colitis (UC) - with the...
22.
Hird E, Ohmuro N, Allen P, Moseley P, Kempton M, Modinos G, et al.
Schizophr Bull
. 2022 Dec;
49(2):339-349.
PMID: 36516396
Background And Hypothesis: Around 20% of people at clinical high risk (CHR) for psychosis later develop a psychotic disorder, but it is difficult to predict who this will be. We...
23.
Schirmbeck F, van der Ven E, Boyette L, McGuire P, Valmaggia L, Kempton M, et al.
Front Psychiatry
. 2022 Aug;
13:869023.
PMID: 35942478
Objective: People at ultra-high risk (UHR) for psychosis have a high prevalence of tobacco smoking, and rates are even higher among the subgroup that later develop a psychotic disorder. However,...
24.
Tognin S, Richter A, Kempton M, Modinos G, Antoniades M, Azis M, et al.
Schizophr Bull Open
. 2022 Jul;
3(1):sgac040.
PMID: 35903803
Objective: To examine the association between baseline alterations in grey matter volume (GMV) and clinical and functional outcomes in people at clinical high risk (CHR) for psychosis. Methods: 265 CHR...
25.
Hedges E, See C, Si S, McGuire P, Dickson H, Kempton M
Psychol Med
. 2022 Jul;
52(11):2009-2016.
PMID: 35821623
Persons at clinical high-risk for psychosis (CHR) are characterised by specific neurocognitive deficits. However, the course of neurocognitive performance during the prodromal period and over the onset of psychosis remains...
26.
Kerins S, Nottage J, Salazar de Pablo G, Kempton M, Tognin S, Niemann D, et al.
Front Psychiatry
. 2022 Apr;
13:828376.
PMID: 35370849
Background: The clinical high-risk for psychosis (CHR-P) paradigm was introduced to detect individuals at risk of developing psychosis and to establish preventive strategies. While current prediction of outcomes in the...
27.
Hedges E, Dickson H, Tognin S, Modinos G, Antoniades M, van der Gaag M, et al.
Schizophr Res Cogn
. 2022 Mar;
28:100222.
PMID: 35242602
Robust deficits in cognitive functioning are present in people with psychosis and are evident in the early stages of the disorder. Impairments in verbal memory and verbal fluency are reliably...
28.
Krajner F, Hadaya L, McQueen G, Sendt K, Gillespie A, Avila A, et al.
Schizophrenia (Heidelb)
. 2022 Mar;
8(1):13.
PMID: 35236831
The neurobiological effects of clozapine are under characterised. We examined the effects clozapine treatment on subcortical volume and cortical thickness and investigated whether macrostructural changes were linked to alterations in...
29.
van der Heijden H, Schirmbeck F, Kempton M, van der Gaag M, Allott K, Nelson B, et al.
Eur Psychiatry
. 2022 Feb;
65(1):e17.
PMID: 35225210
No abstract available.
30.
Zahid U, Hedges E, Dimitrov M, Murray R, Barker G, Kempton M
Psychiatry Res Neuroimaging
. 2022 Feb;
321:111446.
PMID: 35131573
Longitudinal MRI is used in clinical research studies to examine illness progression, neurodevelopment, and the effect of medical interventions. Such studies typically report changes in brain volume of less than...